| Coronavirus Antivirals |
|
| Cat. No. |
Product Name |
Activity |
| 4499 |
(+)-JQ1 |
Inhibits ACE2 and TMPRSS2 transcription
and blocks infection by SARS-CoV-2; potent and selective BET bromodomain
inhibitor |
| 4274 |
AP 24534 |
Identified as
targeting human proteins in the SARS-CoV-2 interactome; potent multi-kinase
and pan-Bcr-Abl inhibitor |
| 7283 |
Apilimod dimesylate |
Inhibits cellular
entry by SARS-CoV-2, MERS-CoV and MHV S pseudovirions; potent and selective
PIKfyve inhibitor |
| 7235 |
Arbidol |
Inhibits
replication of SARS-CoV-2 in vitro; broad spectrum antiviral |
| 7755 |
Asunaprevir |
Inhibits SARS-CoV-2
Mpro activity; also inhibits hepatitis C virus NS3 protease |
| 3771 |
Azithromycin |
Predicted to
disrupt binding of SARS-CoV-2 spike protein to ACE2 |
| 7222 |
Baricitinib |
In
silico modelling predicts inhibition of SARS-CoV-2 cell entry; highly
potent JAK inhibitor |
| 3193 |
Camostat mesylate |
Inhibits entry of
SARS-Cov-2 into lung cells; TMPRSS2 inhibitor |
| 4109 |
Chloroquine
diphosphate |
Inhibits SARS-CoV-2
infection in vitro |
| 7485 |
Covidcil-19 |
Inhibits viral
propagation and viral infectivity of SARS-CoV-2 |
| 970 |
Cycloheximide |
Exhibits
anti-MERS-CoV activity in vitro; protein synthesis inhibitor |
| 1101 |
Cyclosporin A |
Inhibits
coronavirus replication; cyclophilin inhibitor |
| 7223 |
Dabrafenib mesylate |
Targets human
proteins in the SARS-CoV-2 interactome; potent and selective B-Raf, CDK16 and
NEK9 inhibitor |
| 6793 |
Dasatinib |
Inhibits
replication of SARS-CoV and MERS-CoV in vitro; potent pan-Src/Bcr-Abl
inhibitor |
| 1467 |
Daunorubicin
hydrochloride |
Identified as
targeting human proteins in the SARS-CoV-2 interactome; DNA topoisomerase II
inhibitor |
| 4583 |
Digoxin |
Exhibits
anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor |
| 7336 |
Dinaciclib |
Exhibits antiviral
activity against SARS-CoV-2 in vitro; potent and selective inhibitor of
CDK2, CDK5, CDK1 and CDK9 |
| 3807 |
Disulfiram |
SARS-CoV-2
Mpro inhibitor; also reversibly stimulates SERCA Ca2+-ATPase |
| 4545 |
E 64d |
Inhibts entry of
SARS-CoV-2 into lung cells in combination with Camostat (Cat. No.
3193); cathepsin inhibitor |
| 5245 |
Ebselen |
Inhibits SARS-CoV-2
Mpro in vitro; glutathione peroxidase mimic |
| 6986 |
EG 00229
trifluoroacetate |
Inhibits binding of
cleaved spike protein of SARS-CoV-2 to neuropilin 1 (NRP1); neuropilin 1
antagonist |
| 7231 |
EIDD 1931 |
Inhibits MERS-CoV
and SARS-CoV-2 replication in vitro; viral RNA-dependent RNA polymerase
(RdRP) inhibitor |
| 7225 |
Favipiravir |
Reduces infection
rate of SARS-CoV-2 in vitro; viral RNA polymerase inhibitor |
| 3631 |
FK 506 |
Identified as
targeting human proteins in the SARS-CoV-2 interactome; potent calcineurin
inhibitor |
| 7229 |
Galidesivir
dihydrochloride |
Broad spectrum
antiviral nucleotide; inhibits coronavirus replication in vitro |
| 3259 |
Gemcitabine
hydrochloride |
Inhibits
replication of coronaviruses; DNA synthesis inhibitor |
| 7280 |
GRL 0617 |
Coronavirus PLpro
inhibitor |
| 7227 |
GS 441524 |
Displays antiviral
activity against MERS-CoV, SARS-CoV and SARS-CoV-2; viral RNA-dependent RNA
polymerase (RdRp) inhibitor; active metabolite of Remdesivir (Cat.
No. 7226) |
| 5303 |
GSK 2194069 |
Inhibits SARS-CoV-2
infection in vitro; human FASN inhibitor |
| 4618 |
GW 6471 |
Blocks SARS-CoV-2
infection in vitro and reduces viral RNA; PPARα antagonist |
| 1416 |
Homoharringtonine |
Inhibits SARS-CoV-2
infection in vitro; inhibits protein synthesis |
| 5648 |
Hydroxychloroquine
sulfate |
Inhibits SARS-CoV-2
viral infection in vitro |
| 5906 |
Imatinib mesylate |
Inhibits
replication of SARS-CoV and MERS-CoV in vitro; potent and selective
v-Abl tyrosine kinase inhibitor |
| 1708 |
Indomethacin |
Identified as
targeting human proteins in the SARS-CoV-2 interactome |
| 5213 |
LL 37 |
Inhibits
interaction between SAR-CoV-2 S1 protein and ACE2; human cathelicidin peptide
derivative |
| 7052 |
Lopinavir |
Inhibits SARS-CoV-2
replication in vitro; highly potent and selective HIV-1 protease
inhibitor |
| 7705 |
Masitinib |
SARS-CoV-2 Mpro
inhibitor |
| 6819 |
Mefloquine
hydrochloride |
Exhibits antiviral
activities against SARS-CoV-2; also Cx36 and Cx50 gap channel blocker |
| 2864 |
Metformin
hydrochloride |
Identified as
targeting human proteins in the SARS-CoV-2 interactome; antidiabetic |
| 7586 |
Molnupiravir |
Prodrug of
antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV
infection |
| 7853 |
Mpro 13b-H |
Negative control
for Mpro 13b-K (Cat. No. 7228) |
| 7228 |
Mpro 13b-K |
Coronavirus
Mpro inhibitor |
| 7695 |
Mpro 61 |
Potent non-covalent
inhibitor of SARS-CoV-2 main protease |
| 7230 |
MPro N3 |
Coronavirus Mpro
inhibitor |
| 8126 |
Mpro Tracer |
SARS-CoV-2 main
protease fluorescent ligand; TR-FRET acceptor |
| 3081 |
Nafamostat mesylate |
Inhibits SARS-CoV-2
infection in vitro; serine protease inhibitor |
| 3766 |
Nelfinavir mesylate |
Exhibits
anti-MERS-CoV activity in vitro; potent HIV-1 protease inhibitor |
| 4079 |
Niclosamide |
Inhibits SARS-CoV-2
spike protein induced syncytia formation and viral replication in vitro;
also STAT3 inhibitor |
| 7234 |
Nitazoxanide |
Inhibits SARS-CoV-2
infection in vitro; Pyruvate flavodoxin/ferredoxin oxidoreductase (PFOR)
inhibitor |
| 1076 |
Ouabain |
Exhibits
anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor |
| 7416 |
Plitidepsin |
Inhibits SARS-CoV-2
replication. Also potent antitumor and protein synthesis inhibitor. |
| 7505 |
PLpro inhibitor 19 |
SARS-CoV-2 PLpro
and viral replication inhibitor |
| 7357 |
PLpro inhibitor 6 |
SARS-CoV and
SARS-CoV-2 PLpro inhibitor |
| 4107 |
Probenecid |
Inhibits SARS-CoV-2
replication and influenza A infection; MRP and OAT3 inhibitor |
| 1125 |
Quercetin |
Inhibits SARS-CoV
Mpro; also non-selective PI 3-kinase inhibitor |
| 1292 |
Rapamycin |
Inhibits MERS-CoV
infection; mTOR inhibitor and immunosuppressant |
| 7226 |
Remdesivir |
Displays antiviral
activity against MERS-CoV, SARS-CoV and SARS-CoV-2; viral RNA-dependent RNA
polymerase (RdRp) inhibitor |
| 4501 |
Ribavirin |
Inhibits cytopathic
effect of SARS-CoV in vitro; guanosine analog and IMPDH inhibitor |
| 5856 |
Ritonavir |
Improves outcome in
an animal model of MERS-CoV infection; HIV protease inhibitor |
| 7064 |
Ruxolitinib |
Targets human
proteins in the SARS-CoV-2 interactome; potent and selective JAK1/JAK2
inhibitor |
| 7191 |
Santacruzamate A |
Identified as
targeting human host proteins that interact with SARS-CoV-2 |
| 7189 |
Saracatinib |
Inhibits MERS-CoV,
other coronaviruses and dengue virus |
| 7760 |
Selinexor |
Potent inhibitor of
SARS-CoV-2 replication in vitro |
| 7192 |
SMIP 004 |
S-phase
kinase-associated protein 2 (SKP2) inhibitor; inhibits MERS-CoV replication
and induces autophagy in infected cells |
| 7554 |
SSYA10-001 |
Potent coronavirus
helicase inhibitor; also inhibits human papillomavirus E6 |
| 1138 |
Thapsigargin |
Inhibits SARS-CoV-2
infection in vitro; SERCA inhibitor |
| 2815 |
Valproic acid,
sodium salt |
Identified as
targeting human proteins in the SARS-CoV-2 interactome; HDAC inhibitor |
| 0654 |
Verapamil
hydrochloride |
Targets human
proteins in the SARS-CoV-2 interactome; CaV1.x blocker |
|
|
|
| ACE2 |
|
|
| Cat. No. |
Product Name |
Activity |
| 1158 |
Angiotensin II |
Potent endogenous
vasoconstrictor peptide; substrate for ACE2 |
| 5213 |
LL 37 |
Inhibitor of
SARS-CoV-2 S1 spike protein and ACE2 interaction |
| 3345 |
MLN 4760 |
Potent and
selective angiotensin-converting enzyme 2 (ACE2) inhibitor |
| 7629 |
Panobinostat |
Suppresses ACE2 and
ABO expression |
| 7486 |
Roxadustat |
Reduces ACE2
expression; orally bioavailable |
|
|
|
| Furin Inhibitor |
|
|
| Cat. No. |
Product Name |
Activity |
| 3501 |
Decanoyl-RVKR-CMK |
Furin inhibitor; blocks SARS-CoV-2 spike protein cleavage and
blocks viral cell entry |
| 5253 |
SSM 3
trifluoroacetate |
Potent furin inhibitor |